European approval of dostarlimab (Jemperli) for recurrent or advanced endometrial cancer
Dostarlimab is first anti-PD-1 therapy approved as monotherapy for the treatment of adults with recurrent or advanced mismatch repair deficient endometrial cancer that has progressed on or following prior treatment with a platinum‑containing regimen.
Source:
Biospace Inc.